Although work with BRD4 inhibitors suggests that multiple MLL-FPs use the same molecular pathway for leukemogenesis (Dawson et al., 2011; Zuber et al., 2011), this cannot explain the fact that MLL-AF4, MLL-AF9, and MLL-ENL produce different leukemias even when expressed in the same cell type (Drynan et al., 2005; Metzler et al., 2006). Here, KMT2A is linked to leukemia.